miR-141-3p、miR-200a在卵巢癌患者外周血中的表达及其对化疗敏感性的预测价值

doi:10.3969/j.issn.1671-7171.2023.03.009

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1201 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the expression of miR-141-3p and miR-200a in the peripheral blood of patients with ovarian cancer and their predictive value for chemosensitivity. 【Methods】 A total of 82 patients with ovarian cancer admitted to the Affiliated Hospital of Yan'an University from October 2015 to September 2020 were selected. They were divided into a non responsive group and a sensitive group based on the chemotherapy efficacy of ovarian cancer patients. The clinical data of the two groups were compared. Logistic regression analysis was used to analyze the risk factors affecting the chemotherapy sensitivity of ovarian cancer patients; The receiver operating characteristics (ROC) curves were plotted to evaluate the predictive efficacy of peripheral blood miR-141-3p and miR-200a in chemosensitivity of ovarian cancer patients using area under curve (AUC). 【Results】 Of the 82 patients with ovarian cancer in this study,27 (32.93%) had no response to chemotherapy. The proportion of patients with stage Ⅳ clinical stage,lymph node metastasis,residual tumor diameter,and miR-141-3p expression level in the non responsive group were higher than those in the sensitive group (P<0.05),while the miR-200a expression level in the non responsive group was lower than that in the sensitive group (P<0.05). Logistic regression analysis showed that clinical stage Ⅳ,expression levels of miR-141-3p and miR-200a in peripheral blood were risk factors affecting chemosensitivity in patients with ovarian cancer (OR=2.732,3.241,3.277,P<0.05). The ROC curve analysis showed that the best cutoff points for predicting chemosensitivity in ovarian cancer patients with peripheral blood miR-141-3p and miR-200a were 1.55 and 1.84,respectively,and the AUC was 0.757 and 0.790,respectively. 【Conclusion】 The expression levels of miR-141-3p and miR-200a in peripheral blood are related to chemosensitivity in patients with ovarian cancer,and can be used as important reference indicators for predicting chemosensitivity in patients with ovarian cancer.

Key words： Ovarian Neoplasms/PA MicroRNAs/AN Antineoplastic Agents

Received: 06 May 2022

PACS:

R737.31

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	REN Juan
	YAN Li-ming
	SHI Xi-mei

Cite this article:

REN Juan,YAN Li-ming,SHI Xi-mei. Expression of miR-141-3p and miR-200a in Peripheral Blood of Patients with Ovarian Cancer and their Predictive Value for Chemosensitivity[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(3): 352-355.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.03.009 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I3/352

[1] JIANG X,LI X,LI W,et al. PARP inhibitors in ovarian cancer:Sensitivity prediction and resistance mechanisms[J].J Cell Mol Med,2019,23(4):2303-2313.
[2] PENSON R T,VALENCIA R V,CIBULA D,et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 Mutation (SOLO3):a randomized phase Ⅲ trial[J].J Clin Oncol,2020,38(11):1164-1174.
[3] 刘娜,曾洁,张小媚,等. miR-200a参与调控卵巢癌化疗敏感性的作用及其机制[J].中华医学杂志,2014,94(27):2148-2151.
[4] 穆卫红,陈文琪,彭园园,等. miR-141-3p表达与卵巢癌细胞顺铂化疗敏感性的相关性研究[J].河北医科大学学报,2020,41(2):49-53.
[5] JAVADI S,GANESHAN D M,QAYYUM A,et al. Ovarian cancer,the revised figo staging system,and the role of imaging[J].AJR Am J Roentgenol,2016,206(6):1351-1360.
[6] 中国抗癌协会妇科肿瘤专业委员会.卵巢恶性肿瘤诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(7):739-749.
[7] EISENHAUER E A,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[8] 王冰,徐臻,赵虎,等. 卵巢癌患者血清miR-210、miR-126与临床病理特征及预后关系探讨[J].中国计划生育学杂志,2019,27(2):221-225.
[9] 王晓雯. miR-141-3p在化疗耐药与敏感上皮性卵巢癌组织中的表达分析及其靶基因预测和验证[D]. 太原:山西医科大学,2017.
[10] 周勤芬,鲍正娟,张锐,等. miRNA-200家族与晚期卵巢癌化疗疗效和预后的关系[J].现代妇产科进展,2016,25(3):178-181.
[11] RICCIARDELLI C,LOKMAN N A,SABIT I,et al. Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics[J].Cancer Lett,2018,421(8):51-58.
[12] 王颖欣,李昌英,何胜利. 病理因素及化疗因素与上皮性卵巢癌预后关系分析[J].现代中西医结合杂志,2015,24(36):4066-4068.
[13] 杜趁香,王焱,武海英. 过表达miR-141-3p通过靶向下调PTEN并激活PI3K/Akt信号通路促进卵巢癌A2780细胞的恶性生物学行为[J].中国肿瘤生物治疗杂志,2019,26(5):563-568.
[14] 刘佳宇,赵妍蕊,张丽娜,等. 上皮源性卵巢癌中4种miRNAs的表达及其临床意义[J].天津医药,2015,43(9):996-1000.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(3): 441-443.